Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D₂ and Serotonin 1A and 2A Receptors in C. elegans.

ABSTRACT: The atypical antipsychotic aripiprazole is a Food and Drug Administration-approved drug for the treatment of psychotic, mood, and other psychiatric disorders. Previous drug discovery efforts pinpointed aripiprazole as an effective suppressor of Machado-Joseph disease (MJD) pathogenesis, as its administration resulted in a reduced abundance and aggregation of mutant Ataxin-3 (ATXN3) proteins. Dopamine partial agonism and functional selectivity have been proposed as the main pharmacological mechanism of action of aripiprazole in the treatment of psychosis; however, this mechanism remains to be determined in the context of MJD. Here, we focus on confirming the efficacy of aripiprazole to reduce motor dysfunction in vivo, using a Caenorhabditis elegans (C. elegans) model of

SUBMITTER: Jalles A 

PROVIDER: S-EPMC8962381 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature